AUPH is the ticker symbol for Aurinia Pharmaceuticals Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks AUPH with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is AUPH a good stock to buy?

13F Pro's AI ranking engine scores AUPH at 75.3/100, ranked #96 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for AUPH is available at https://13fpro.ai/company/AUPH. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source AUPH data?

All Aurinia Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. Aurinia Pharmaceuticals Inc. files with the SEC under CIK 1600620. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Aurinia Pharmaceuticals Inc. AUPH

NasdaqMid CapHealthcare

13F Pro quality score

Rank #96 of 2,925TOP 5%

Why it scores 75 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$83.22M

Quarter to Jun 30

Net income

$37.41M

Quarter to Jun 30

Free cash flow

$52.57M

Quarter to Jun 30

Operating margin

55.7%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$1.32B total

TANG CAPITAL MANAGEMENT LLC

$221.36M+6.7%

BlackRock, Inc.

$139.04M+4.4%

GOLDMAN SACHS GROUP INC

$95.36M+292.0%

NEA Management Company, LLC

$67.37M0.0%

TWO SIGMA INVESTMENTS, LP

$58.84M+1.1%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$55.39M-0.6%

STATE STREET CORP

$43.95M+2.5%

MORGAN STANLEY

$39.17M+3.4%

MARSHALL WACE, LLP

$34.69M+9.0%

GEODE CAPITAL MANAGEMENT, LLC

$28.86M+10.8%

RENAISSANCE TECHNOLOGIES LLC

$26.27M-7.0%

D. E. Shaw & Co., Inc.

$23.90M-10.5%

VANGUARD PORTFOLIO MANAGEMENT LLC

$23.06M+8.2%

JACOBS LEVY EQUITY MANAGEMENT, INC

$20.90M+12.2%

JUPITER ASSET MANAGEMENT LTD

$18.57M+36.2%

LSV ASSET MANAGEMENT

$18.32M+3.8%

NOMURA HOLDINGS INC

$16.61M+1.0%

AQR CAPITAL MANAGEMENT LLC

$16.10M0.0%

NORTHERN TRUST CORP

$14.65M+4.8%

Nuveen, LLC

$13.80M+24.4%

Jupiter Topco LLC

$10.22M--

DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt

$10.12M-3.0%

PRUDENTIAL FINANCIAL INC

$9.88M-1.4%

O'SHAUGHNESSY ASSET MANAGEMENT, LLC

$9.63M+37.1%

Hillsdale Investment Management Inc.

$9.35M+162.5%

See all 282 institutional holders →

What's Driving AUPH's Business? Latest 10-Q Breakdown

19/19 datapoints verified

AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue rose to $83.2M on LUPKYNIS net product sales of $79.4M (+19% YoY), with net income of $37.4M after income tax expense jumped to $11.4M.

Biggest Revenue Drivers

Net product sales (LUPKYNIS)$79.4M+19% YoY

Increase in LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration

License, collaboration and royalty revenue$3.8M+12% YoY

Primarily manufacturing services provided to Otsuka for sharing capacity of the Monoplant

Biggest Revenue Drivers

Total revenue: $83.2M

Net product sales (LUPKYNIS)$79.4M+19% YoY

Increase in LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration

License, collaboration and royalty revenue$3.8M+12% YoY

Primarily manufacturing services provided to Otsuka for sharing capacity of the Monoplant

Largest Expense Items

Selling, general and administrative$23.5M-$2.5M YoY

Lower share-based compensation tied to March 2026 officer departures and reversals from forfeited unvested awards

Research and development$13.1M+$5.6M YoY

Higher employee-related costs supporting development activities and increased clinical supply and distribution

Cost of revenue$6.6M-7% YoY

Decrease in sales of LUPKYNIS inventory to Otsuka, which has a low gross margin

Other (income) expense, net$(6.2)Mvs $9.2M expense YoY

Favorable foreign exchange remeasurement of the Swiss Franc-denominated Monoplant finance lease liability and settlement of a former officer obligation

Margins: Gross margin was 92% for the quarter versus 90% a year earlier, as lower-margin LUPKYNIS inventory sales to Otsuka declined. Company expects SG&A to stay consistent with 2025 and R&D to increase.

Watch Items from the Filing

Revenue depends on two specialty pharmacies, one specialty distributor and partner Otsuka — all customers for accounting purposes — plus a single commercial product, LUPKYNIS.
Income tax expense rose to $11.4M from $0.6M; effective rate 23.3% versus 2.9%, as the 2025 valuation allowance release left no unrecognized deferred tax assets to offset tax.
Kezar acquisition closed May 11, 2026 for $55.5M total consideration, treated as an asset acquisition; $3.7M contingent value right liability recorded plus $23.1M deferred tax benefits.
Monoplant finance lease requires a quarterly fixed fee of CHF 3.6 million through March 31, 2030; lease liability stands at $60.4M with FX remeasurement swinging other income.
Repurchased 2.5M shares for $38.1M in the quarter ($213.4M program-to-date); $86.6M remains authorized, with no buybacks in June 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AUPH

Earnings Per Share

13fpro.ai/company/AUPH

Loading ratio trend…

Aurinia Pharmaceuticals Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$283.1M	$287.2M	37.1%
FY 2024	10-K	$235.1M	$5.8M	-2.0%
FY 2023	10-K	$175.5M	$-78.0M	-52.2%
FY 2022	10-K	$134.0M	$-108.2M	-83.2%
FY 2021	10-K	$45.6M	$-181.0M	—
FY 2020	10-K	$50.1M	$-102.7M	—

About Aurinia Pharmaceuticals Inc. (AUPH): stock profile, AI score and financials

Aurinia Pharmaceuticals Inc. (AUPH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUPH at 75.3/100 on a composite quality score built from its SEC filings, placing it at rank #96 of 2,925 stocks — the top 5% of the AI-ranked universe. AUPH scores in the top quartile across balance sheet strength (99.4), profitability (99.3), free cash flow (96.3). Areas of concern include revenue scale (30.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Aurinia Pharmaceuticals Inc. reports quarterly revenue of $83.2M, net income of $37.4M, an operating margin of 55.7%. Top institutional holders of AUPH by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock, GOLDMAN SACHS GROUP, based on the most recent SEC filings. AUPH trades on the Nasdaq exchange and files with the SEC under CIK 1600620. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aurinia Pharmaceuticals Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1600620 →

Aurinia Pharmaceuticals Inc. AUPH

Top Institutional Holders

What's Driving AUPH's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

AUPH key financials by period

AUPH insiders

About Aurinia Pharmaceuticals Inc. (AUPH): stock profile, AI score and financials

Aurinia Pharmaceuticals Inc. AUPH

Top Institutional Holders

What's Driving AUPH's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

AUPH key financials by period

Companies similar to AUPH

AUPH insiders

About Aurinia Pharmaceuticals Inc. (AUPH): stock profile, AI score and financials